News Release

RIBOMIC Announces Completion of 50% of Enrollment of its Phase 2 Clinical Trial for Wet Age-Related Macular Degeneration (TOFU Study)

TOKYO, February 1, 2021 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that it has completed subject enrollment* of more than 50% of the ongoing Phase 2 trial (TOFU) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary.

“This is an important milestone for the company. This has been possible due to the great support we received from our subjects, clinical investigators and our trial partners. So far, we have observed an excellent safety profile. There has only been one mild, drug-related AE of inflammation at the injection site in the anterior chamber, which resolved within one week following treatment with topical corticosteroid. We believe that the novel mechanism of RBM-007 will provide another option for patients suffering from wAMD” said Yusuf Ali, Ph.D., CEO of RIBOMIC USA Inc.

Despite COVID-19, RIBOMIC remains on track to complete TOFU by the end of 2021 as had been planned before the pandemic.

In addition, the enrollment of the Phase 2 extension study (RAMEN) is also progressing well. Continued interest from clinical investigators in this extension study fueling the momentum required for the RAMEN study to also be completed by the end of 2021.

*randomized subjects including early termination

About RBM-007 and development background

RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients. However, a significant portion of wet AMD patients exhibit incomplete response to therapy, and over the extended management course can lose vision, with the formation of submacular fibrosis as one risk factor. RIBOMIC investigated a novel therapy for wet AMD targeting fibroblast growth factor 2 (FGF2), which is implicated in not only angiogenesis but also fibrosis in several diseases, and created RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity. RBM-007 is chemically synthesized, and pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and relatively long-lasting profiles, which are superior to the other approved anti-VEGF drugs. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD.

About TOFU study

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 monotherapy and RBM-007 in

Combination with Eylea® Compared to Eylea® Monotherapy in Subjects with Wet Age-related Macular Degeneration (TOFU Study) is Phase 2 Study assessing the safety, efficacy and durability of RBM-007.

Study Design	Multicenter, active-controlled, double masked study
Patient Population	Patients with wet AMD who are non or low responders to existing anti-VEGF drugs
Administration	Four monthly intravitreal injections of RBM-007. Eylea® dosed every other month as per label.
Primary Endpoints	Mean change in Best Corrected Visual Acuity from Baseline and safety
Study Arms	RBM-007 (monotherapy) RBM-007 and Eylea®（Anti-VEGF drug）(combination) Eylea® (Anti-VEGF drug) (monotherapy)
Number of Subject	81 (27 per arm)
Duration	5 months (primary endpoint at month 1 after last injection)
Location	Approximately 10 sites across the United States

See ClinicalTrials.gov for more information.
https://clinicaltrials.gov/ct2/show/NCT04200248

About RAMEN study
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects with Wet Age-related Macular Degeneration (RAMEN study) is a multi-center, open label, extension study assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet AMD.

Study Design	Multi-center, open-label study
Patient Population	Subjects who have completed all visits in TOFU Study and meet eligibility criteria
Administration	Four monthly intravitreal injections of RBM-007
Primary Endpoints	Mean change in Best Corrected Visual Acuity from Baseline and Safety
Key Secondary Endpoints	Change from Baseline in characteristics of fibrosis Change from Baseline in central subfield thickness (CST) and macular volume
Study Arms	RBM-007 (2.0 mg)

Number of Subject	Approximately 40
Duration	5 months (primary endpoint at month 1 after last injection)
Location	Around 10 sites across the United States

See ClinicalTrials.gov for more information.
https://clinicaltrials.gov/ct2/show/NCT04640272

About wet Age-related Macular Degeneration

Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.

ABOUT RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company develops aptamer therapeutics, within the fast-growing field of nucleic acid medicine. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other problems.
See RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Corporate Planning Department
ir.inquiry@ribomic.com